BioPharma Drive: Drug Pricing

FEBRUARY 12, 2024

European venture firm Medicxi built the startup by combining six of its portolio companies, similar to when it merged 10 startups to form Centessa Pharmaceuticals in 2021.

Disease 162

Disease Pharmaceuticals Drugs 162

Drug Target Review

NOVEMBER 7, 2024

Introduction Therapeutic antibodies have proven to be indispensable medicines for addressing the most debilitating diseases. Agonist antibodies in immunological diseases Agonist antibodies targeting immune checkpoint pathways are increasingly recognised and investigated for their potential in immunological diseases.

Disease 52

Disease Immune Response Regulations Engineering 52

Drugs.com

JULY 13, 2023

THURSDAY, July 13, 2023 -- More kids in the United States are getting a developmental disability diagnosis, with prevalence close to 9% in 2021, the U.S. Centers for Disease Control and Prevention reports. Among 3- to 17-year-olds, 8.56% have ever.

Disease 189

Disease 189

Broad Institute

APRIL 5, 2025

The organization has honored Liu for the development of the gene editing platforms base editing and prime editing, which can correct the vast majority of known disease-causing genetic variations and have already been used in at least 15 clinical trials, with life-saving results.

Science 144

Science Clinical Trials DNA Disease 144

The Pharma Data

AUGUST 1, 2021

per share dividend for the third quarter of 2021. The dividend will be paid on September 8, 2021, to all stockholders of record as of the close of business on August 17, 2021. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Disease 52

Disease 52

Drug Discovery Today

FEBRUARY 17, 2021

LONDON, 17 February 2021 – Smiths Detection, a global leader in threat detection and security screening technologies, today reports that its BioFlash® Biological Identifier is capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

Disease 113

Disease Research 113

Drug Discovery Today

JANUARY 25, 2021

OSLO/LONDON, JANUARY 20 2021: EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company today announced a collaboration with GE Healthcare to develop an innovative ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across multiple disease conditions.

Therapies 113

Therapies Disease 113

The Pharma Data

AUGUST 1, 2021

to $6.14; Raises 2021 Adjusted Diluted EPS Guidance Range from $12.37 Based upon the momentum of our business, we are raising our full year 2021 EPS guidance and believe AbbVie is very well positioned for the long term.” ” Second-Quarter Results. Worldwide net revenues were $13.959 billion, an increase of 33.9

Treatment 52

Treatment FDA Trials Disease 52

Drug Target Review

OCTOBER 25, 2024

How does precision neuroscience differ from traditional approaches in the treatment of neurodegenerative diseases, and what advantages does it offer? Traditionally, Alzheimer’s disease is diagnosed by clinical examination, medical history and cognitive testing. We believe we are at a breakthrough moment in Alzheimer’s disease research.

Disease 59

Disease Clinical Trials Therapies Science 59

Broad Institute

JUNE 10, 2024

The advance, from the lab of Broad core institute member David Liu , could one day help researchers develop a single gene therapy for diseases such as cystic fibrosis that are caused by one of hundreds or thousands of different mutations in a gene.

DNA 144

DNA Engineering Therapies Disease 144

The Pharma Data

AUGUST 19, 2021

AbbVie today announced the start of its two-week public voting period for the 2021 Thriving Undergraduate and Thriving Graduate Scholarship. These inspiring scholars now have the chance to earn additional scholarship funding in the amount of $22,000 if selected as the 2021 Thriving Undergraduate or Graduate Student.

Disease 52

Disease Production Marketing 52

Drug Target Review

FEBRUARY 8, 2024

3 Moreover, younger CRC patients have been shown to present with more advanced stages of the disease. Gene sequencing The team utilised gene sequencing technology to compare tissue samples taken from 136 young-onset colorectal cancer patients with 140 average-age patients with the disease. 2021 April 22 [2024 February 6]; 13(9):2025.

Disease 105

Disease Research Drugs 105

The Pharma Data

JULY 29, 2021

today announced that it will report its second quarter financial results on Tuesday, August 3, 2021, after the close of the U.S. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. financial markets.

Disease 52

Disease Marketing 52

The Pharma Data

OCTOBER 14, 2021

The results, which demonstrate that patients treated with Biogen’s portfolio of MS therapies mount an effective antibody response to COVID-19 vaccination, are being presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual meeting, October 13-15, 2021. Source link: [link].

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

JULY 29, 2021

today reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance across the company. “We Reports Second Quarter Revenues of $11.7 and Non-GAAP EPS of $1.93 board chair and chief executive officer, Bristol Myers Squibb. “We

Production 52

Production International Licensing Licensing 52

Drug Target Review

JULY 4, 2023

In practice, some patients may be left managing a syndrome associated with the therapy along with the disease. For instance, we can compare the data from the 2021 DESTINY gastric cancer trial using the ADC Trastuzumab Deruxtecan with data from a gastric cancer trial in 2004 using the small molecule Irinotecan. Colombo R, Rich JR.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

KIF1A

MARCH 16, 2024

Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. Like hereditary spastic paraplegia, CMT is an umbrella disorder, associated with mutations in over 140 genes, but many diagnosed patients do not know their disease-causing mutation.

Disease 105

Disease Clinical Development Research Treatment 105

biobide

SEPTEMBER 15, 2023

The need to protect crops from pests, disease, and weeds has existed for centuries, with the Roman’s having used ash, crushed cypress leaves and diluted urine to protect their crops. In 2021, the UK government introduced new “Maximum Residue Levels”. Pesticides are a vital tool in safeguarding the world’s food supply.

Regulations 112

Regulations Government Disease Production 112

Drug Target Review

SEPTEMBER 21, 2023

Some report that they believe that if they don’t take the medication, they may develop onchocerciasis-related severe skin diseases and may go blind (river blindness) and would prefer a treatment that does not repeat every year. Need for adulticidal drugs More than 99 percent of countries worldwide has been affected by this disease.

Drugs 105

Drugs Treatment Disease Research 105

The Pharma Data

SEPTEMBER 29, 2021

Presentations: 535P, 536P, 534P, 104P, 1534P, 444P, 630P, LBA26, 623P, 603P, 593P, 594P, 1309P, 606P, 590P, 826O, 530P, LBA58, 1520O, 48P, 508TiP, 505TiP, 509TiP, 1438TiP Bayer will present new data from its established portfolio of approved oncology therapies at the upcoming ESMO Congress 2021 from September 16-21, 2021.

Research 52

Research Clinical Trials Therapies Trials 52

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 49

Disease Therapies Pharmaceuticals Clinical Trials 49

Chemical Biology and Drug Design

OCTOBER 10, 2023

Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. million people worldwide were living with HIV in 2021. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) data, 38.4 million

FDA Approval 100

FDA Approval Clinical Trials FDA Virus 100

The Pharma Data

AUGUST 30, 2021

Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments. Wilson disease.

Disease 52

Disease Trials Therapies Treatment 52

KIF1A

OCTOBER 14, 2023

Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. But the opposite relationship is just as important: knowing which diseases are associated with a symptom means earlier diagnosis, and an earlier search for other potential symptoms.

Disease 105

Disease Treatment Research Production 105

The Pharma Data

AUGUST 5, 2021

and described today in eLife, may help expedite the process by helping scientists find promising, existing drugs that might be repurposed for these diseases. Further studies are now necessary to validate that these drugs can be repurposed for this disease. 2021 Aug 3;10:e65543. The database, called NICEdrug.ch

Disease 52

Disease Drugs Laboratories Treatment 52

LifeSciVC

NOVEMBER 17, 2023

This year we start with a deep dive into the biomedical innovation across our industry – “putting the Big back into Big Pharma” with obesity and Alzheimer’s, and the state of play across other disease areas, industry R&D productivity, and the risks facing the sector. As usual, we close with a brief update on Atlas itself.

Science 107

Science Marketing Production Disease 107

The Pharma Data

MAY 31, 2022

the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). of BRT-DA01 in patients with Parkinson’s disease.?. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 The purpose of the?Ph1

Trials 52

Trials Disease Clinical Trials Engineering 52

The Pharma Data

MARCH 16, 2022

(Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease. In June 2021, the U.S.

Disease 52

Disease Clinical Trials Trials Treatment 52

The Pharma Data

SEPTEMBER 30, 2021

a pioneering biotech company developing novel intranasal vaccines and therapies to assist patients defeat debilitating diseases, including COVID-19. a pioneering biotech company developing novel intranasal vaccines and therapies to assist patients defeat debilitating diseases, including COVID-19. doi: 10.1016/j.isci.2021.103037.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

AUGUST 7, 2021

Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells. Targeted delivery to clear glycogen in muscle cells.

FDA Approval 52

FDA Approval Disease FDA Treatment 52

DrugBank

JUNE 27, 2023

Out of the millions of genetic variants present in human populations, GWAS are designed to uncover those associated with specific traits or diseases. 9 Polygenic diseases are much more common, and thousands of genetic variants with very small effects could impact their phenotype.

Disease 98

Disease Treatment Drugs Clinical Trials 98

Broad Institute

SEPTEMBER 15, 2023

We apply STACI to analyze the spatio-temporal progression of Alzheimer’s disease and identify the associated nuclear morphometric and coupled gene expression features.

Disease 40

Disease 40

Drug Target Review

NOVEMBER 29, 2023

We focus on patients who are resilient to disease and conduct an unbiased search for protective autoantibodies in these patients that may underlie their resiliency. There is a huge push for multiplexed biological readouts, coupled with more advanced translatable model systems that capture more of the complexity of human neurological diseases.

Engineering 111

Engineering Drug Development Disease Treatment 111

Broad Institute

JULY 10, 2023

Credit: Allison Colorado, Broad Communications Arriving in the Bay Area after a childhood in increasingly diverse surroundings, Martin became acutely aware of health disparities and the profound differences in disease prevalence among different populations. I wanted to know how I could have any impact on studying genetic diversity.”

Disease 98

Disease Bioinformatics Medical Schools Research 98

LifeSciVC

APRIL 26, 2024

With just over 60 new biotechs raising their first round of financing, the sector’s company formation activity has slowed 50-60% from its historic peak in 2021. Further, this lemming challenge has also moved well beyond oncology – think of all the “not-so-fast follower” autoimmune programs or metabolic disease stories.

DNA 125

DNA Science Marketing Clinical Trials 125

Eye on FDA

JANUARY 26, 2022

That said, the last two letters – the final one of 2021 and the first of 2022 both went to the same company – Lilly. Note: In a prior posting reviewing 2021 regulatory actions, it was stated that FDA issued 5 regulatory action letters for the year.

FDA 108

FDA Production Drugs Disease 108

The Pharma Data

NOVEMBER 5, 2021

The data were presented at the American Society of Nephrology (ASN) 2021 Annual Meeting. Novartis moment blazoned that a Phase II study of investigational iptacopan (LNP023) – a first-in- class, oral, picky factor B asset – in cases with C3 glomerulopathy (C3G) met primary endpoints in both patient cohorts1.

Disease 52

Disease Treatment Pharmacokinetics FDA 52